浩欧博(688656.SH)：与罗氏诊断就化学发光自身抗体检测产品领域开展合作

Core Viewpoint - The signing of the framework agreement between the company and Roche Diagnostics is a significant step in implementing the company's long-term development strategy, focusing on the field of chemiluminescent self-antibody testing products [1] Group 1: Partnership Details - The framework agreement was signed on October 21, 2025, in Suzhou, and serves as a foundational and guiding document for mutual cooperation projects between the company and Roche Diagnostics [1] - The agreement does not involve specific financial amounts, indicating a focus on collaboration rather than immediate financial commitments [1] Group 2: Strategic Implications - The collaboration is expected to enhance the company's brand recognition in the domestic market, which is crucial for expanding its market share in the diagnostic reagent sector [1] - The partnership will facilitate communication and learning between the two entities, allowing the company to continuously improve its capabilities and provide higher quality products and services to customers [1]